Our Dual-Solution Approach

Combining precision therapeutics with next-generation biotech infrastructure

Therapeutics Division

Precision Gene Editing Therapy

Developing CRISPR-based therapies targeting disease-causing genetic variants in Crohn's disease.

Single-Treatment Approach

Designed for one-time treatment aimed at functional cure, not lifelong symptom management.

Advanced Delivery Systems

Novel delivery mechanisms specifically engineered for gastrointestinal targeting and safety.

Currently in foundational stage
Building toward pre-clinical development

Platform Division

Biotech Operating System

Building comprehensive software infrastructure to accelerate modern biotech development.

Enterprise-Grade Tools

Data integration, trial management, regulatory compliance, and collaboration suites.

Industry Impact

Designed to accelerate drug development by 2-3x while reducing compliance costs by millions.

Dual revenue potential:
Therapeutics + SaaS platforms

Why ViroDyn

Unique positioning at the intersection of precision medicine and enterprise software

UK Biotech Innovation

Leveraging the UK's supportive regulatory environment and world-class life sciences ecosystem for breakthrough therapeutics.

Dual Revenue Streams

Combining high-impact therapeutics with scalable SaaS platforms creates multiple pathways to market success.

Protected Innovation

Our proprietary gene editing approach and delivery systems are developed with comprehensive IP protection strategies.

Our Journey

From vision to clinical reality

2025 - Present

Company Established

ViroDyn founded with dual focus on CRISPR therapeutics and biotech software platforms. UK incorporation complete.

2026 - Post Pre-Seed

Pre-Clinical Development

Begin active development of our proprietary gene editing approach. Building manufacturing partnerships and establishing scientific advisory board.

2028 - Future

Clinical Trials

Planned progression to first-in-human trials following MHRA and FDA gene therapy guidelines. Platform beta launches to strategic partners.

Leadership Team

Bringing together expertise in genetics, computational biology, and business development

Alexander Humphries

Alexander Humphries

Co-Founder & CTO

Geneticist and computational biologist driving ViroDyn's AI-driven therapeutic development team and the platform development.

Sinan Weston

Sinan Weston

Co-Founder & CEO

Business development and product strategy leader with genetics background. Responsible for company vision, partnerships, and commercialization strategy.

Building our advisory board - Seeking world-class experts in gene therapy, regulatory affairs, and biotech commercialization

Join the Mission

Multiple pathways to participate in the future of precision medicine

Partnership Opportunities

Research collaborations, clinical partnerships, and technology pilot programs. Let's advance medicine together.

Investment Opportunity

Seed stage investment opportunity. SEIS/EIS eligible with dual revenue potential from therapeutics and SaaS platforms.

Join Our Team

Building the future of biotech requires exceptional talent. Advisor opportunities and key positions available.

Full methodology and detailed technical approach available under NDA for qualified partners and investors